5Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int, 1998,53 (4) : 836 - 844.
6Schieppati A, Ruggenenti P, Cornejo RP, et al. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. JASN, 1992,2 ( 11 ) : 1640 - 1644.
7Hollenbeck M, Kutkuhn B, Aul C, et al. Haemolytic - uraemic syndrome and thrombotic- thrombocytopenic purpura in adults: clinical findings and prognostic factors for death and end - stage renal disease. Nephrol Dial Transplant, 1998,13( 1 ) : 76 - 81.
8Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol, 2003,120 (4): 556 - 573.
2Gottschall JL, Elliot W, Llanos E, et al. Quinine - induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood, 1991,77(2) : 306 -310.
3Savasan S,Lee SK,Ginsburg D,et al. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood, 2003,101 ( 11 ) : 4449 - 4451.
4Knottnerus JA,Dinant GJ. Medicine based evidence,a prerequisite for evidence based medicine. BMJ, 1997,315(7116): 1109- 1110.
5Fearing MK, Spar MD, Kahn MJ. Chronic thrombotic thrombocytopenic purpura masquerading as other disease entities.J La State Med Soc,1998,150(1):29- 31.
6Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura -hemolytic - uremic syndrome. Transfusion, 2000,40 (8) : 896- 901.
7Perdue JJ, Chandler LK, Vesely SK, et al. Unintentional platelet removal by plasmapheresis. J Clin Apher, 2001,16 (2):55 -60.
8Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher,2001,16(1) : 19 - 22.
9Chang JC, Aly ES. Acute respiratory distress syndrome as a major dinical manifestation of thrombotic thrombocytopenic purpura. Am J Med Sci, 2001,321 (2) : 124 - 128.
10Newman MF, Kirchner JL, Phillips- Bute B, et al. Longitudinal assessment of neurocognitive function after contrary- artery bypass surgery. N Engl J Med,2001,344(6) :395 -402.
4Lip GY, Beevers M, Beevers G. The failure of malignant hyper-tension to decline: a survey of 24 years experience in a multira-cial population in England. J Hypertens, 1994,12 (11 ) : 1297 -1305.
5Kadiri S,Olutade BO. The clinical presentation of malignant hy-pertension in Nigerians. J Hum Hypertens, 1991,5(4): 339 -343.
6Kawazoe N,Eto T,Abe I,et al. Long term prognosis of malign -ant hypertension : difference between underlying diseases such asessential hypertension and chronic glomerulonephtitis. Clin Neph-rol, 1988,29(2) : 53 -57.
7Lip GY, Bevers M, Beevers DG. Complications and survival of315 patients with malignant - phase hypertension. J Hypertens,1995,13(8) :915 -924.
